{"paper_id": "5b4c3a9d24cfa20950217e8b1a172944be62aa70", "metadata": {"title": "Clinical Studies Update Updates from Ongoing Clinical Trials", "authors": [{"first": "Alexandra", "middle": [], "last": "Abrams-Downey", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Q1", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Joseph", "middle": [], "last": "Saabiye", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Monica", "middle": [], "last": "Vidaurrazaga", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "Currently there are no therapeutics approved by the US point) compared to placebo (p = 0.001) [22] . On May 1, 2020,", "cite_spans": [{"start": 94, "end": 98, "text": "[22]", "ref_id": "BIBREF1"}], "ref_spans": [], "section": "Introduction"}, {"text": "a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . damage seen in COVID-19 is due to a \"cytokine storm\", 100 release of proinflammatory cytokines including IL-6 ", "cite_spans": [], "ref_spans": [], "section": "Introduction"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "National Institutes of Health. NIAID strategic plan for COVID-19", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "National Institutes of Health. NIH clinical trial shows remdesivir 205 accelerates recovery from advanced COVID-19", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Fact sheet for health care pro-209 viders. Emergency use authorization (EUA) of remdesivir (GS-210 5734)", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Some observations of treating cases of diphtheria", "authors": [{"first": "G", "middle": ["B"], "last": "Dunmire", "suffix": ""}], "year": null, "venue": "JAMA", "volume": "XXI", "issn": "", "pages": "853--860", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Meta-analysis: con-213 valescent blood products for Spanish influenza pneumonia: a future 214 H5N1 treatment?", "authors": [{"first": "T", "middle": ["C"], "last": "Luke", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Kilbane", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Jackson", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Hoffman", "suffix": ""}], "year": 2006, "venue": "Ann Intern Med", "volume": "145", "issn": "", "pages": "599--609", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "The effective-216 ness of convalescent plasma and hyperimmune immunoglobulin 217 for the treatment of severe acute respiratory infections of viral 218 etiology: a systematic review and exploratory meta-analysis", "authors": [{"first": "J", "middle": [], "last": "Mair-Jenkins", "suffix": ""}, {"first": "M", "middle": [], "last": "Saavedra-Campos", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Baillie", "suffix": ""}], "year": 2015, "venue": "J Infect Dis", "volume": "211", "issn": "", "pages": "80--90", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Hyperimmune IV immunoglobulin 220 treatment: a multicenter double-blind randomized controlled trial 221 for patients with severe 2009 influenza A (H1N1) infection", "authors": [{"first": "Ifn", "middle": [], "last": "Hung", "suffix": ""}, {"first": "Kkw", "middle": [], "last": "To", "suffix": ""}, {"first": "C", "middle": ["K"], "last": "Lee", "suffix": ""}], "year": 2013, "venue": "Chest", "volume": "222", "issn": "", "pages": "464--73", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Evaluation of 224 convalescent plasma for Ebola virus disease in Guinea", "authors": [{"first": "J", "middle": [], "last": "Van Griensven", "suffix": ""}, {"first": "T", "middle": [], "last": "Edwards", "suffix": ""}, {"first": "X", "middle": [], "last": "De Lamballerie", "suffix": ""}], "year": 2016, "venue": "N Engl J Med", "volume": "225", "issn": "", "pages": "33--42", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Testing an old therapy against a new disease: convalescent 227 plasma for COVID-19", "authors": [{"first": "R", "middle": [], "last": "Rubin", "suffix": ""}], "year": null, "venue": "JAMA", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1001/228jama.2020.7456"]}}, "BIBREF9": {"ref_id": "b9", "title": "Treatment of 5 critically ill patients 230 with COVID-19 with convalescent plasma", "authors": [{"first": "C", "middle": [], "last": "Shen", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wang", "suffix": ""}, {"first": "F", "middle": [], "last": "Zhao", "suffix": ""}], "year": 2020, "venue": "JAMA", "volume": "323", "issn": "", "pages": "1582--1591", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Effect of convale Q8 scent plasma therapy 233 on viral shedding and survival in COVID-19 patients", "authors": [{"first": "Q", "middle": ["L"], "last": "Zeng", "suffix": ""}, {"first": "Z", "middle": ["J"], "last": "Yu", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Gou", "suffix": ""}], "year": null, "venue": "J Infect Dis", "volume": "234", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1093/infdis/jiaa228.235"]}}, "BIBREF12": {"ref_id": "b12", "title": "Effectiveness of convalescent plasma 236 therapy in severe COVID-19 patients", "authors": [{"first": "K", "middle": [], "last": "Duan", "suffix": ""}, {"first": "B", "middle": [], "last": "Liu", "suffix": ""}, {"first": "C", "middle": [], "last": "Li", "suffix": ""}], "year": null, "venue": "Proc Natl Acad Sci U S A", "volume": "237", "issn": "2020", "pages": "9490--9496", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Early safety indicators 239 of COVID-19 convalescent plasma in 5,000 patients. medRxiv pre-240 print", "authors": [{"first": "M", "middle": [], "last": "Joyner", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Wright", "suffix": ""}, {"first": "D", "middle": [], "last": "Fairweather", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.05.12.20099879.241"]}}, "BIBREF15": {"ref_id": "b15", "title": "cytokine storm in SARS patients", "authors": [], "year": 2005, "venue": "J Med Virol", "volume": "75", "issn": "", "pages": "185--94", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Analysis of serum cytokines in patients with 244 severe acute respiratory syndrome", "authors": [{"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhan", "suffix": ""}], "year": 2004, "venue": "Infect Immun", "volume": "72", "issn": "", "pages": "4410--4415", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Cytokine release syn-246", "authors": [{"first": "D", "middle": ["T"], "last": "Teachey", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Rheingold", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Maude", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "FDA approval summary: tocilizumab for 249 syndrome", "authors": [{"first": "", "middle": [], "last": "Le", "suffix": ""}, {"first": "L", "middle": [], "last": "Li", "suffix": ""}, {"first": "W", "middle": [], "last": "Yuan", "suffix": ""}], "year": 2018, "venue": "Oncologist", "volume": "23", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Effective treatment of severe COVID-19 patients 252 with tocilizumab", "authors": [{"first": "X", "middle": [], "last": "Xu", "suffix": ""}, {"first": "M", "middle": [], "last": "Han", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Proc Natl Acad Sci U S A", "volume": "117", "issn": "", "pages": "10970--10975", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Tocilizumab 254 COVID-19 pneumonia", "authors": [], "year": null, "venue": "AP-HP", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Press release. Regeneron and Sanofi provide update on 257", "authors": [{"first": "", "middle": [], "last": "Regeneron", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Phase 2/3 adaptive-designed trial of KEVZARA (sarilumab) in 258 hospitalized COVID-19 patients. Regeneron", "authors": [{"first": "U", "middle": ["S"], "last": "", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Ethics of random-260", "authors": [{"first": "A", "middle": ["J"], "last": "London", "suffix": ""}, {"first": "O", "middle": ["O"], "last": "Omotade", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Mello", "suffix": ""}, {"first": "G", "middle": ["T"], "last": "Keusch", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Treating COVID-19-off-label drug use, compassionate use, and 263 randomized clinical trials during pandemics", "authors": [{"first": "A", "middle": ["C"], "last": "Kalil", "suffix": ""}], "year": 2020, "venue": "JAMA", "volume": "323", "issn": "", "pages": "1897--1905", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "Finding effective treatments for COVID", "authors": [{"first": "J", "middle": ["L"], "last": "Goodman", "suffix": ""}, {"first": "L", "middle": [], "last": "Borio", "suffix": ""}], "year": null, "venue": "", "volume": "19", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "reviewed Press release with limited preliminary data; not peerreviewed CRP = C-reactive protein; ICU = intensive care unit; MOD = multisystem organ dysfunction; MV = mechanical ventilation; NIV = noninvasive ventilation; RCT = randomized controlled trial. Published 22 April 22, 2020. www.niaid.nih.gov/sites/ 147 default/files/NIAID-COVID-19-Strategic-Plan-2020.pdf. [2] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effec-148 tively inhibit the recently emerged novel coronavirus (2019-nCoV) dosing design of hydroxychloroquine for the treat-154 ment of severe acute respiratory syndrome coronavirus 2 (SARS-155CoV-2). Clin Infect Dis. In press. https://doi.org/10.1093/cid/ciaa237.[6] Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect 156 of a combination hydroxychloroquine and azithromycin in 157 80 COVID-19 patients with at least a six-day follow-up: a pilot 158 observational study. Travel Med Infect Dis 2020;34:101663. [7] Magagnoli J., Narendran S., Pereira F., et al. Outcomes of hydroxy-159 chloroquine usage in United States veterans hospitalized with Covid-160 19. medRxiv preprint. https://doi.org/10.1101/2020.04.16.20065920. [8] Geleris J., Sun Y., Platt J., et al. Observational study of hydroxy Q3 chlor-161 oquine in hospitalized patients with Covid-19. N Engl J Med. In 162 press. https://doi.org/10.1056/NEJMoa2012410. [9] Rosenberg E.S., Dufort E.M., Udo T., et al. Associ Q4 ation of treatment 163 with hydroxychloroquine or azithromycin with in-hospital mortal-164 ity in patients with COVID-19 in New York State. JAMA. In press. 165 https://doi.org/10.1001/jama.2020.8630. 166 [10] Mahevas M, Tran VT, Roumier M, et al. Clinical efficacy of hydro-167 xychloroquine in patients with covid-19 pneumonia who require 168 oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844. http://dx.doi.org/10.1136/bmj.m1844. 169 [11] Mahevas M., Tran V.-T., Roumier M., et al. No evidence of clinical 170 efficacy of hydroxychloroquine in patients hospitalized for COVID-171 19 infection with oxygen requirement: results of a study using 172 routinely collected data to emulate a target trial. medRxiv preprint. 173 https://doi.org/10.1101/2020.04.10.20060699. 174 [12] Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of 175 chloroquine diphosphate as adjunctive therapy for patients hospital-176 ized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-177 2) infection: a randomized clinical trial. JAMA Netw Open 2020;3: 178 e208857. http://dx.doi.org/10.1001/jamanetworkopen.2020.8857. 179 [13] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with 180 mainly mild to moderate coronavirus disease 2019: open label, 181 randomized control trial. BMJ 2020;369:m1849. http://dx.doi.org/ 182 10.1136/bmj.m1849. 183 [14] ClinicalTrials.gov. Accessed May 15, 2020. https://clinicaltrials.gov. 184 [15] Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharma Q5 co-185 logic treatments for coronavirus disease 2019 (COVID-19): a review. 186 JAMA. In press. https://doi.org/10.1001/jama.2020.6019. 187 [16] Yin W., Mao C., Luan X., et al. Structural basis for inhibi Q6 tion of the 188 RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. 189 Science. In press. https://doi.org/10.1126/science.abc1560. 190 [17] de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic 191 remdesivir (GS-5734) treatment in the rhesus macaque model of 192 MERS-CoV infection. Proc Natl Acad Sci U S A 2020;117:6771-6. 193 [18] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-Williamson B.N., Feldmann F., Schwarz B., et al. Clinical benefit of 196 remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv 197 preprint. https://doi.org/10.1101.2020.04.15.043166. 198 [20] Grein J., Ohmagari N., Shin D., et al. Compassio Q7 nate use of remde-", "latex": null, "type": "figure"}, "TABREF1": {"text": "c o m / e u f o c u s the FDA issued an emergency use authorization for remde-", "latex": null, "type": "table"}, "TABREF2": {"text": "Key clinical trials for COVID-19 treatments that are currently under way.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>ACTT [22] </td><td>Convalescent Plasma EAP [33] </td><td>CORIMUNO-TOCI [39] </td><td>Regeneron [40]\n</td></tr><tr><td>Trial ID </td><td>NCT04280705 </td><td>NCT0433860 </td><td>NCT0433180839 </td><td>NCT04315298\n</td></tr><tr><td>Study agent </td><td>Remdesivir </td><td>Convalescent plasma </td><td>Tocilizumab </td><td>Sarilumab\n</td></tr><tr><td>Study location </td><td>International </td><td>USA </td><td>France </td><td>USA\n</td></tr><tr><td>Study design </td><td>Adaptive, double-blind, placebo RCT\n</td><td>Open-label expanded access program\n</td><td>Open-label RCT </td><td>Adaptive, phase 2/3, randomized, double-blind, placebo-controlled\n</td></tr><tr><td>Patients </td><td>1063 </td><td>5000 </td><td>129 </td><td>457\n</td></tr><tr><td>Median age, yr (range)\n</td><td>Not reported </td><td>62.3 (18.5-97.8) </td><td>Not reported </td><td>Not reported\n</td></tr><tr><td>Male patients </td><td>Not reported </td><td>3153 (63.1%) </td><td>Not reported </td><td>Not reported\n</td></tr><tr><td>Disease status </td><td>Not reported </td><td>Severe or life-threatening: 4051\n</td><td>Moderate or severe (number not reported)\n</td><td>Severe: 28%\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(81%)\n</td><td>\u00a0</td><td>Critical: 49%\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>High risk of disease progression: 949 (19%)\n</td><td>\u00a0</td><td>MOD: 23%\n</td></tr><tr><td>Baseline clinical status\n</td><td>Not reported </td><td>Total ICU admissions: 3316 (66%) Respiratory failure: 2912 (72%)\nMOD/failure: 745 (18.4%)\n</td><td>All patients required O2\nsupplementation, but levels not specified\n</td><td>Not reported\n</td></tr><tr><td>Clinical improvement\n</td><td>Median time to recovery: remdesivir 11 d vs placebo 15 d (p &lt; 0.001)\n</td><td>Septic shock: 600 (14.8%)\n</td><td>Significantly lower proportion of patients in tocilizumab arm met primary outcome (need for NIV or MV) at day 14\n</td><td>All patients met primary endpoint (% change in CRP): \n21% placebo vs 77% sarilumab 200 mg vs 79% sarilumab 400 mg\nClinical improvement (critical): 18 (41%) placebo vs 48 (51%) sarilumab 200 mg vs 52 (59%) sarilumab 400 mg\n</td></tr><tr><td>Not reported </td></tr><tr><td>Death </td><td>Remdesivir 8.0%;\n</td><td>7-d mortality rate: 14.9% </td><td>Significantly lower proportion of patients in tocilizumab arm\n</td><td>Critical: 12 (27%) placebo vs 34\n</td></tr><tr><td>placebo 11.6%\n</td><td>\u00a0</td><td>(36%) sarilumab 200 mg vs 20\n</td></tr><tr><td>\u00a0</td><td>(p = 0.059)\n</td><td>\u00a0</td><td>met primary outcome (death) at day 14\n</td><td>(23%) sarilumab 400 mg\n</td></tr><tr><td>Serious adverse events\n</td><td>Not reported </td><td>4 h after transfusion: 36 (&lt;1%) including transfusion-associated circulatory overload (7); transfusion-related acute lung injury (11); severe allergic transfusion reactions\n</td><td>Not reported </td><td>No new safety signals\n</td></tr><tr><td>Limitations </td><td>Press release with limited preliminary data; not peer-reviewed\n</td><td>No control group; study not designed to assess efficacy of convalescent plasma care unit; MOD = multisystem organ </td><td>Press release with limited preliminary data; not peer-reviewed\n</td><td>Press release with limited preliminary data; not peer-reviewed dysfunction; MV = mechanical ventilation; NIV = noninvasive ventilation;\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>CRP = C-reactive protein; ICU = intensive </td></tr></table></body></html>"}}, "back_matter": []}